8-K
Adagio Medical Holdings, Inc. (ADGM)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) ofthe Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):March 31, 2025
ADAGIO MEDICAL HOLDINGS, INC.
(Exact name of registrant as specified in itscharter)
| Delaware | 001-42199 | 99-1151466 |
|---|---|---|
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
| 26051 Merit Circle, Suite 102<br><br> <br>Laguna Hills, CA | 92653 | |
| --- | --- | |
| (Address of principal executive offices) | (Zip Code) |
(949) 348-1188
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br><br> <br>Symbol(s) | Name of each exchange<br><br> <br>on which registered |
|---|---|---|
| Common Stock, par value $0.0001 per share | ADGM | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and FinancialCondition.
On March 31, 2025, Adagio Medical Holdings, Inc. (the “Company”), issued a press release announcing the Company’s financial results for the fiscal year ended December 31, 2024. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 7.01. Regulation FD Disclosure.
On March 31, 2025, the Company issued a press release regarding the appointment of Deborah Kaster as the Company’s Chief Business Officer. A copy of the press release is being furnished as Exhibit 99.2 and is incorporated herein by reference.
The information in this Item 7.01 of this Current Report on Form 8-K is being “furnished” and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, and shall not be incorporated or deemed to be incorporated by reference into any filing by the Company under the Securities Act or the Exchange Act, regardless of any general incorporation language contained in such filing, unless otherwise expressly stated in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description |
|---|---|
| 99.1 | Press Release, dated March 31, 2025 |
| 99.2 | Press Release, dated March 31, 2025 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 2, 2025
| Adagio Medical Holdings, Inc. | |
|---|---|
| By: | /s/ Todd Usen |
| Name: | Todd Usen |
| Title: | Chief Executive Officer |
3
Exhibit 99.1
Adagio Medical Reports Fourth Quarter and FullYear 2024 Results
LAGUNA HILLS, CA, March 31, 2025 – Adagio Medical Holdings, Inc. (Nasdaq: ADGM), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2024.
Recent Business Highlights:
| · | Reported total company revenue of $137 thousand in the fourth quarter of 2024, compared to $78 thousand in the fourth quarter of 2023.<br>Full year revenue for 2024 was $0.6 million compared to $0.3 million in 2023. |
|---|---|
| · | Surpassed 40% enrollment in the FULCRUM-VT pivotal study. The results of the study will be used<br>to support FDA premarket approval (PMA) for Adagio’s VT Cryoablation System for endocardial ablation of scar-mediated ventricular<br>tachycardia (VT). The study, which seeks to enroll 206 patients with ischemic and non-ischemic disease at 20 U.S. and Canadian<br>centers, is on track for completion of patient enrollment in the second half of 2025. |
| --- | --- |
| · | Announced focused realignment of resources to prioritize its FULCRUM-VT US pivotal investigational device exemption clinical trial<br>activities and its new product design optimization program. |
| --- | --- |
| · | Reported cash, cash equivalents, and short-term investments of $20.6 million as of December 31, 2024. |
| --- | --- |
“2024 was a pivotal year for Adagio, as we successfully commenced enrollment in our FULCRUM pivotal trial, securing the strategy to establish Adagio as a leading provider of treatments for ventricular tachycardia (“VT”). I am thrilled that the trial is enrolling ahead of expectations, bringing us even closer to providing a solution to this underserved patient population,” said Todd Usen, Chief Executive Officer of Adagio. “With all of our resources today focused on two initiatives, the FULCRUM study and our product design optimization program, Adagio is well-poised to deliver on our critical mission of improving the quality of life and long-term outcomes for patients with VT.”
Fourth Quarter 2024 Financial Results
Revenue was $137 thousand for the fourth quarter of 2024, up 76% compared to $78 thousand for the fourth quarter of 2023. The increase over the prior year quarter was driven primarily by the introduction of vCLAS in Europe.
Gross margin was negative 1012% for the fourth quarter of 2024, compared to negative 328% for the fourth quarter of 2023. The year-over-year change was primarily due to increased sales volume.
Operating expenses for the fourth quarter of 2024 were $56.7 million, compared to $5.1 million for the fourth quarter of 2023. The increase was mainly driven by impairment of $49.2 million and increased transaction and public company expenses.
Net loss was $57.4 million for the fourth quarter of 2024 compared to a net loss of $8.6 million in the same period of the prior year. The increase in net loss was primarily driven by impairment loss.
Full Year 2024 Financial Results
Revenue was $0.6 million for the full year of 2024, up 101% compared to $0.3 million for the full year of 2023. The increase over the prior year was driven primarily by the introduction of vCLAS in Europe.
Gross margin was negative 451% for full year of 2024, compared to negative 335% for the full year of 2023. The year-over-year change was primarily due to increased sales volume.
Operating expenses for the full year of 2024 were $81.4million, compared to $26.9 million for the full year of 2023. The increase was mainly driven by impairment and increased transaction and public company expenses.
Net loss was $75.0 million for the full year of 2024 compared to a net loss of $36.6 million in the prior year. The increase in net loss was primarily driven by impairment loss.
About Adagio Medical Holdings, Inc.
Adagio Medical is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Cryoablation (“ULTC”) technology. ULTC is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The Company is currently focused on the treatment of ventricular tachycardia ("VT") with its purpose-built vCLAS catheter, which is CE Marked and is currently under evaluation in the FULCRUM-VT U.S. IDE Pivotal Study.
About FULCRUM VT
FULCRUM-VT (Feasibility of Ultra-Low Temperature Cryoablation in Recurring Monomorphic Ventricular Tachycardia) is a prospective, multi-center, open-label, single-arm study, enrolling 206 patients with structural heart disease of both ischemic and non-ischemic cardiomyopathy, indicated for catheter ablation of drug refractory ventricular tachycardia (VT) in accordance with current treatment guidelines. The results of the study will be used to obtain FDA premarket approval (PMA) for Adagio’s VT Cryoablation System with the vCLAS™ cryoablation catheter with industry broadest indication for purely endocardial ablation of scar-mediated VT.
Forward-Looking Statements
Certain statements in this press release (this “Press Release”) may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of the Company. For example, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of the Company and could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain. The Company cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in the definitive proxy/final prospectus relating to the Business Combination, which was filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”), and described in other documents filed by the Company from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. The Company cannot assure you that the forward-looking statements in this communication will prove to be accurate.
Nothing in this Press Release should be regarded as a representation or warranty by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved, in any specified time frame, or at all. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made in this Press Release. Subsequent events and developments may cause those views to change. The Company does not undertake any duty to update these forward-looking statements.
Media Contact
Ilya Grigorov
Vice President, Global Marketing and Product Management
igrigorov@adagiomedical.com
Investor Contact
Caroline Corner, PhD
ICR Healthcare
IR@adagiomedical.com
Exhibit 99.2
Adagio Medical Appoints Deborah Kaster as Chief Business Officer
LAGUNA HILLS, CA, March 31, – Adagio Medical (Nasdaq: ADGM), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, is pleased to announce the appointment of Deborah Kaster as Chief Business Officer (CBO). Kaster brings more than 25 years of leadership experience in strategy, mergers and acquisitions, corporate finance, investor relations and strategic communications in the medical technology sector.
Most recently, Kaster served as Vice President of Investor Relations at Shockwave Medical, where she played a pivotal role in the company’s growth from IPO to its acquisition by Johnson & Johnson. During her time at Shockwave, the company’s stock price appreciated nearly 2000%, a testament to her strategic vision and communications expertise.
Kaster's career spans a wide range of roles where she has consistently demonstrated her ability to drive corporate strategy and business development. As Director of Business Development at Kyphon, she led the company in a competitive bidding process for St. Francis Medical Technologies, which resulted in Kyphon’s successful $725 million acquisition of St. Francis Medical and, almost immediately subsequent, the ultimate $4 billion acquisition of Kyphon by Medtronic.
“Debbie’s deep expertise in corporate strategy, business development and communications, combined with her relationships and experience on Wall Street, will be instrumental as Adagio Medical enters its next phase of growth,” said Todd Usen, Chief Executive Officer of Adagio Medical. “We are thrilled to welcome Debbie to the team and are confident that her leadership will drive value for our stakeholders and accelerate our mission to revolutionize treatment for patients with ventricular tachycardia.”
At Adagio Medical, Kaster will oversee business development, strategic partnerships, investor relations and corporate communications, working as part of the senior leadership team to advance the company’s objectives and vision.
“I am excited to join Adagio Medical at such a transformative time for the company,” said Kaster. “The potential to make a meaningful impact in the EP space is immense, and I look forward to contributing to Adagio’s success and helping drive the company’s growth strategy.”
Kaster’s distinguished career includes senior roles at Gilmartin Group and in the medical technology investment banking group at Piper Jaffray. She has advised and led strategic initiatives for numerous public and private companies in the medical technology sector. Kaster holds an MBA in Finance and Strategic Management from The Wharton School at the University of Pennsylvania and a Bachelor of Arts in Economics from Cornell University.
About Adagio Medical
Adagio Medical is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Cryoablation (“ULTC”) technology. ULTC is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The Company is currently focused on the treatment of ventricular tachycardia ("VT") with its purpose-built vCLAS catheter, which is CE Marked and is currently under evaluation in the FULCRUM-VT U.S. IDE Pivotal Study.
Contact:
Caroline Corner, PhD
ICR Healthcare
IR@adagiomedical.com